226 related articles for article (PubMed ID: 21892943)
21. Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy.
Holly R; Morton GC; Sankreacha R; Law N; Cisecki T; Loblaw DA; Chung HT
Brachytherapy; 2011; 10(4):299-305. PubMed ID: 21190903
[TBL] [Abstract][Full Text] [Related]
22. Derivation of in vivo source tracking error thresholds for TRUS-based HDR prostate brachytherapy through simulation of source positioning errors.
Poder J; Carrara M; Howie A; Cutajar D; Bucci J; Rosenfeld A
Brachytherapy; 2019; 18(5):711-719. PubMed ID: 31175015
[TBL] [Abstract][Full Text] [Related]
23. The effect of patient inhomogeneities in oesophageal 192Ir HDR brachytherapy: a Monte Carlo and analytical dosimetry study.
Anagnostopoulos G; Baltas D; Pantelis E; Papagiannis P; Sakelliou L
Phys Med Biol; 2004 Jun; 49(12):2675-85. PubMed ID: 15272681
[TBL] [Abstract][Full Text] [Related]
24. A CT-based analytical dose calculation method for HDR 192Ir brachytherapy.
Poon E; Verhaegen F
Med Phys; 2009 Sep; 36(9):3982-94. PubMed ID: 19810471
[TBL] [Abstract][Full Text] [Related]
25. Measurement of craniocaudal catheter displacement between fractions in computed tomography-based high dose rate brachytherapy of prostate cancer.
Kim Y; Hsu IJ; Pouliot J
J Appl Clin Med Phys; 2007 Sep; 8(4):1-13. PubMed ID: 18449148
[TBL] [Abstract][Full Text] [Related]
26. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging (MRI) markers for MRI-guided high-dose-rate brachytherapy: novel marker-flange for cervical cancer and marker catheters for prostate cancer.
Schindel J; Muruganandham M; Pigge FC; Anderson J; Kim Y
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):387-93. PubMed ID: 23433797
[TBL] [Abstract][Full Text] [Related]
28. Dosimetric equivalence of nonstandard HDR brachytherapy catheter patterns.
Cunha JA; Hsu IC; Pouliot J
Med Phys; 2009 Jan; 36(1):233-9. PubMed ID: 19235391
[TBL] [Abstract][Full Text] [Related]
29. IRIDIUM-192 RADIOTHERAPY BENEFITS IN THE MANAGEMENT OF GYNECOLOGICAL TUMORS.
Ivankova VS; Domina EA; Khrulenko TV; Baranovska LM; Hrinchenko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():569-578. PubMed ID: 33361862
[TBL] [Abstract][Full Text] [Related]
30. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
31. In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer.
Anagnostopoulos G; Baltas D; Geretschlaeger A; Martin T; Papagiannis P; Tselis N; Zamboglou N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1183-91. PubMed ID: 14575851
[TBL] [Abstract][Full Text] [Related]
32. Contrast effects on dosimetry of a partial breast irradiation system.
Kassas B; Mourtada F; Horton JL; Lane RG
Med Phys; 2004 Jul; 31(7):1976-9. PubMed ID: 15305449
[TBL] [Abstract][Full Text] [Related]
33. Dose uncertainty due to computed tomography (CT) slice thickness in CT-based high dose rate brachytherapy of the prostate cancer.
Kim Y; Hsu IC; Lessard E; Pouliot J; Vujic J
Med Phys; 2004 Sep; 31(9):2543-8. PubMed ID: 15487736
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a TG-43 compliant analytical dosimetry model in clinical 192Ir HDR brachytherapy treatment planning and assessment of the significance of source position and catheter reconstruction uncertainties.
Pantelis E; Papagiannis P; Anagnostopoulos G; Baltas D; Karaiskos P; Sandilos P; Sakelliou L
Phys Med Biol; 2004 Jan; 49(1):55-67. PubMed ID: 14971772
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric analysis of 3D image-guided HDR brachytherapy planning for the treatment of cervical cancer: is point A-based dose prescription still valid in image-guided brachytherapy?
Kim H; Beriwal S; Houser C; Huq MS
Med Dosim; 2011; 36(2):166-70. PubMed ID: 20488690
[TBL] [Abstract][Full Text] [Related]
36. Validation of a novel robot-assisted 3DUS system for real-time planning and guidance of breast interstitial HDR brachytherapy.
Poulin E; Gardi L; Barker K; Montreuil J; Fenster A; Beaulieu L
Med Phys; 2015 Dec; 42(12):6830-9. PubMed ID: 26632040
[TBL] [Abstract][Full Text] [Related]
37. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation.
Ricke J; Wust P; Wieners G; Beck A; Cho CH; Seidensticker M; Pech M; Werk M; Rosner C; Hänninen EL; Freund T; Felix R
J Vasc Interv Radiol; 2004 Nov; 15(11):1279-86. PubMed ID: 15525748
[TBL] [Abstract][Full Text] [Related]
38. Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer.
Hosni A; Carlone M; Rink A; Ménard C; Chung P; Berlin A
Radiother Oncol; 2017 Jan; 122(1):103-108. PubMed ID: 27916416
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of interfractional variation of organs and displacement of catheters during high-dose-rate interstitial brachytherapy for gynecologic malignancies.
Lee S; Rodney E; Traughber B; Biswas T; Colussi V; Podder T
Brachytherapy; 2017; 16(6):1192-1198. PubMed ID: 28993108
[TBL] [Abstract][Full Text] [Related]
40. 3D CT-based high-dose-rate breast brachytherapy implants: treatment planning and quality assurance.
Das RK; Patel R; Shah H; Odau H; Kuske RR
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1224-8. PubMed ID: 15234059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
